American Regent, a manufacturer of pharmaceuticals for human and veterinary use, completed the acquisition of HBT Labs, a pharmaceutical company. Financial terms were not disclosed. "Our acquisition of HBT Labs supports our growing product portfolio, efforts to expand into the oncology market, and dedication to better meeting the needs of providers and patients. HBT's proprietary processes and technologies to produce complex drugs will enable us to achieve our business objectives of applying innovative thinking to respond to customer needs. We look forward to working with the management team and respected staff of HBT, who are leaders in highly specialized drugs and delivery systems," Paul Diolosa, American Regent President and CEO.